INTRODUCTION {#s1}
============

Gastric cancer (GC) is ranked fifth for cancer incidence and second for cancer deaths, and one in 36 men and 1 in 84 women develop stomach cancer before age 79 \[[@R1]\]. The histologic classification of gastric carcinoma has been based on the Lauren \[[@R2]\] and 2010 WHO classification systems, which recognize four histological subtypes \[[@R3]\]. Neither the Lauren nor the WHO system is particularly clinically useful, as their prognostic and predictive capabilities cannot adequately guide patient management. Thus, new classifications are needed for GC to provide insights into pathogenesis and the identification of new biomarkers and novel treatment targets \[[@R4]\]. Recently, advances in technology and high-throughput analysis have improved our understanding of the genetic basis of GC. To provide a roadmap for patient stratification and trials of targeted therapies, the Cancer Genome Atlas (TCGA) Research Network has characterized 295 primary gastric adenocarcinomas and proposed a new classification of four different tumor subtypes of *Epstein-Barr* virus (EBV)-positive, microsatellite instability (MSI), genomically stable (GS), and chromosomal instability (CIN) subtypes. \[[@R5]\]. The Asian Cancer Research Group (ACRG) also provided a new classification for GC, identifying four subtypes: MSI, MSS/EMT, MSS/TP53 (+), and MSS/TP53(--). One of the most important aspects of the ACRG classification is that it correlates the molecular subtypes with clinical prognosis \[[@R6]\].

*Helicobacter pylori* has been accepted as a causative organism in GC \[[@R7], [@R8]\], and EBV is also now regarded as a GC-causing infectious agent. The original type of EBV-infected GC makes up 5-10% of all GC cases \[[@R9], [@R10]\]. The vast majority of GC arise sporadically, and an inherited component contributes to \<3% of gastric cancers \[[@R11], [@R12]\]. The GC is a heterogeneous disease characterized by epidemiologic and histopathologic differences across countries \[[@R7], [@R8], [@R13], [@R14]\]. Here, we investigated germline mutations in *CDH1, MSH2, MLH1, TP53, APC,* and *STK11,* which are associated with hereditary diffuse gastric cancer, hereditary nonpolyposis colon cancer, Li--Fraumeni syndrome, familial adenomatous polyposis, and Peutz--Jeghers syndrome, respectively \[[@R11], [@R12], [@R15]--[@R19]\]. Furthermore, we studied associations between the genetic aberrant profiles of cancer-related genes, environmental factors (*EBV* and *H. pylori*), and histopathological features in Korean GC patients. We also classified molecular subtypes of Korea GC.

RESULTS {#s2}
=======

Clinical and pathological findings of 107 Korean GC patients {#s2_1}
------------------------------------------------------------

The male to female ratio was 2:1 with median patient age of 70 years (range, 32-90). The intestinal type, diffuse type, and mixed type by Lauren classification accounted for 54.2%, 26.2%, and 19.6%, respectively. In addition, for GC classified according to the 2010 WHO classification, the tubular type (64.5%) was observed with the highest frequency, while the poorly cohesive type and mixed type accounted for 13.1% and 15.0%, respectively. More than half of the tumors were located in the antrum or antrum body, while about 7.5% were located in the cardia and gastroesophageal junction. Fifty-two cases (48.6%) were in stages III-IV, and 66 (61.7%) were *H.pylori*-positive. The clinicopathological findings of the 107 GC patients are summarized in Table [1](#T1){ref-type="table"}.

###### Clinicopathological characteristics of patients with gastric cancer (n=107)

  Characteristics                       Number
  ------------------------------------- ---------------------------------------------
  **Age (year)**                        
  Median (range)                        70 (32 ∼ 90)
  **Sex**                               
  Female                                36 (33.6%)
  Male                                  71 (66.4%)
  **Lauren class**                      
  Diffuse                               28 (26.2%)
  Intestinal                            58 (54.2%)
  Mixed                                 21 (19.6%)
  **WHO class**                         
  Mucinous                              3 (2.8%)
  Tubular                               69 (64.5%)
  Poorly cohesive                       14 (13.1%)
  Mixed (Tubular_Poorly cohesive)       16 (15.0%)
  Uncommon histologic variants          5 (4.7%)
  **pT stage**                          
  T1a/T1b                               9 (8.4%)/15 (14.0%)
  T2                                    11 (10.3%)
  T3                                    38 (35.5%)
  T4a/T4b                               33 (30.8%)/1 (0.9%)
  **pN stage**                          
  N0/N1/N2/N3                           40 (37.4%)/16 (15.0%)/20 (18.7%)/31 (29.0%)
  **M stage**                           
  M0/M1                                 102 (95.3%)/5 (4.7%)
  **AJCC stage**                        
  Stages IA/IB                          18 (16.8%)/11 (10.3%)
  Stages IIA/IIB                        13 (12.1%)/13 (12.1%)
  Stages IIIA/IIIB/IIIC                 17(15.9%)/11 (10.3%)/19 (17.8%)
  Stage IV                              5 (4.7%)
  **Anatomical regions**                
  GEJ_Cardia                            8 (7.5%)
  Fundus_Body                           36 (34.3%)
  Antrum                                54 (50.5%)
  Antrum_Body                           5 (4.7%)
  Pylorus                               3 (2.8%)
  Diffuse                               1 (0.9%)
  **Epstein-Barr virus infection**      
  Negative                              100 (93.5%)
  Positive                              7 (6.5%)
  **Microsatellite instability(MSI)**   
  MSS                                   88 (82.2%)
  MSI-I                                 4 (3.7%)
  MSI-H                                 15 (14.0%)
  ***H. pylori* infection**             
  Negative                              41 (38.3%)
  Positive                              66 (61.7%)

Abbreviations: GEJ, gastroesophageal junction; *H. pylori, Helicobacter pylori;* pT stage, pathological assessment of the primary tumor; pN stage, pathological assessment of the regional lymph nodes.

Germline variation analysis of hereditary cancer-predisposing syndrome {#s2_2}
----------------------------------------------------------------------

A total of 30 germline variants were observed in *TP53, STK11, ALK, APC, MSH2, MLH1,* and *CDH1* (Table [2](#T2){ref-type="table"}). Among these, 16 variants, 12 variants, and 2 variants were classified as \'Benign or Likely Benign,\' \'VUS,\' and \'Likely pathogenic,\' respectively. Two cases had a likely pathogenic variant (*p.V832M*) in *CDH1* gene.

###### Germline SNPs in *TP53, STK11, ALK, APC, MSH2, MLH1*, and *CDH1* genes of 107 Korean gastric cancer patients

  Sample   Chromosome   Start       End         Ref   Alter   Gene   Transcript ID    Amino acid change   Total depth   VAF(%)(1)^a^   VAF (%)(2)^b^   Clinical significance
  -------- ------------ ----------- ----------- ----- ------- ------ ---------------- ------------------- ------------- -------------- --------------- -----------------------
  YMC 54   2            29449820    29449820    G     A       ALK    NM_004304.4      p.T1012M            637           48.51%         60.36%          Benign
  YMC 7    2            29449820    29449820    G     A       ALK    NM_004304.4      p.T1012M            208           55.77%         43.83%          Benign
  YMC 70   2            29449820    29449820    G     A       ALK    NM_004304.4      p.T1012M            755           52.58%         57.85%          Benign
  SKW 18   2            29519923    29519923    G     A       ALK    NM_004304.4      p.L550F             155           38.06%         55.39%          VUS
  YMC 13   5            112177778   112177778   A     C       APC    NM_001127511.2   p.K2145Q            151           52.32%         33.74%          Benign
  YMC 24   5            112178865   112178865   G     A       APC    NM_001127511.2   p.R2507H            1142          47.90%         49.52%          VUS
  SKW 38   5            112176548   112176548   G     C       APC    NM_001127511.2   p.A1735P            628           45.86%         47.30%          VUS
  SKW 21   5            112173895   112173895   A     C       APC    NM_001127511.2   p.E850D             147           55.78%         50.93%          Benign
  YMC 29   16           68867247    68867247    G     A       CDH1   NM_004360.4      p.V832M             1337          52.21%         49.75%          Likely pathogenic
  YMC 37   16           68867247    68867247    G     A       CDH1   NM_004360.4      p.V832M             1498          50.73%         46.41%          Likely pathogenic
  SKW 16   16           68856080    68856080    C     G       CDH1   NM_004360.4      p.L630V             928           43.74%         40.61%          Benign
  SKW 15   16           68856080    68856080    C     G       CDH1   NM_004360.4      p.L630V             827           49.33%         71.46%          Benign
  YMC 53   3            37053562    37053562    C     T       MLH1   NM_000249.3      p.R217C             1397          46.96%         50.40%          VUS
  YMC 55   3            37042521    37042521    T     G       MLH1   NM_000249.3      p.S95A              233           39.06%         30.52%          VUS
  YMC 6    3            37067240    37067240    T     A       MLH1   NM_000249.3      p.V384D             578           48.79%         44.85%          Benign
  YMC 70   3            37067240    37067240    T     A       MLH1   NM_000249.3      p.V384D             547           51.55%         47.99%          Benign
  YMC 14   3            37053562    37053562    C     T       MLH1   NM_000249.3      p.R217C             1409          45.71%         51.65%          VUS
  YMC 22   3            37067240    37067240    T     A       MLH1   NM_000249.3      p.V384D             862           99.54%         100%            Benign
  YMC 3    3            37090506    37090506    C     A       MLH1   NM_000249.3      p.Q701K             369           51.49%         41.29%          Benign
  YMC 4    3            37089022    37089022    C     G       MLH1   NM_000249.3      p.L582V             364           48.63%         57.47%          VUS
  YMC 37   3            37053562    37053562    C     T       MLH1   NM_000249.3      p.R217C             1315          49.20%         49.76%          VUS
  YMC 48   3            37067240    37067240    T     A       MLH1   NM_000249.3      p.V384D             899           43.38%         44.61%          Benign
  SKW 31   3            37053562    37053562    C     T       MLH1   NM_000249.3      p.R217C             294           55.78%         39.71%          VUS
  YMC 66   2            47656972    47656972    C     T       MSH2   NM_000251.2      p.L390F             197           56.85%         52.78%          Benign
  YMC 15   2            47656972    47656972    C     T       MSH2   NM_000251.2      p.L390F             1281          46.68%         79.62%          Benign
  YMC 28   2            47630344    47630344    C     A       MSH2   NM_000251.2      p.P5Q               231           53.25%         86.79%          VUS
  YMC 5    2            47637371    47637371    A     G       MSH2   NM_000251.2      p.I169V             711           51.34%         45.12%          Likely benign
  YMC 48   2            47656972    47656972    C     T       MSH2   NM_000251.2      p.L390F             692           51.30%         53.31%          Benign
  SKW 41   2            47703564    47703564    G     A       MSH2   NM_000251.2      p.M688I             993           52.57%         50.83%          VUS
  SKW 40   17           7578209     7578209     G     A       TP53   NM_000546.5      p.H214Y             168           39.29%         59.58%          VUS

^a^, tumor tissue; ^b^, matched non-tumor tissue.

Abbreviation: Ref, reference allele; Alter, Altered allele; VAF, Variant allele frequency; VUS, a variant of unknown significance.

Molecular profile of gastric cancer with a 43 gene cancer panel {#s2_3}
---------------------------------------------------------------

To identify driver genes \[[@R20]\] causally linked to tumorigenesis in Korea GCs, variants were extracted from targeted sequencing with a 43 gene cancer panel applied to 107 tumor and matched non-tumor tissues. After mutation calling and stringent filtrations, we identified 317 single-nucleotide variants (SNVs) on coding sequences that included missense variations (n=164, 51.7%), trunc (nonsense and frameshift) variations (n= 110, 34.7%), in-frame variations (n= 42, 13.2%), and splicing site variations (n=1, 0.3%) ([Supplementary Table 2](#SD2){ref-type="supplementary-material"}). Somatic variants detected in each gene for each sample were summarized in [Supplementary Table 3](#SD1){ref-type="supplementary-material"}. Among the 43 genes, we discovered 39 genes that were mutated in one or more individual samples. Among the 107 samples, *TP53* (38.3%), *ARID1A* (36.4%), *CR1* (15.0%), *APC* (11.2%), *BCOR* (11.2%), *CDH1* (10.3%), *CIC* (9.3%), *PIK3CA* (9.3%), *ERBB3* (8.4%), *RHOA* (8.4%), *ERBB2* (7.5%), CCND1 (6.5%), *FBXW7* (6.5%), *ALK* (5.6%), *KRAS* (5.6%), and *MTOR* (5.6%) were identified ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}). Somatic variants were detected in relatively low frequencies (less than 5%) on the *CTNNB1, EGFR, HLA-B, MSH2, PGM5, ZBTB20, IRF2, KDR, LARP4B, MVK, BRAF, PTEN, ACVR1B, CBWD1, FGFR2, JAK2, MEDAG, MLH1, SMAD4, STK11, CD274, MDM2,* and *MYC* genes in this study. We did not detect any somatic variants on the *C16orf74, CCNE1, PDCD1LG2,* or *MET* genes ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}).

Among 317 somatic variants, 110 (34.7%) were recurrently detected in this study (Table [3](#T3){ref-type="table"}). According to the results of somatic variants, *p.Gln1334del/dup* or *p.Asp1850ThrfsTer33* in *ARID1A, p.Arg2194Ter* in *CR1, p.Glu280del* in *CCND1*, *p.Leu15del* in *CDH1, p.Arg678Gln* in *ERBB2, p.Gly13Asp* in *KRAS, p.His1047Arg* in *PIK3CA,* and *p.Pro619LeufsTer43* in *ZBTB20* were recurrently detected in more than four individual cases (Table [3](#T3){ref-type="table"}). Twenty-two copy number variation (CNV)s were identified in the *BCOR* (n=1), *CCND1* (n=2), *CCNE1* (n=3), *ERBB2* (n=5), *FGFR2* (n=1), *KRAS* (n=6), *MYC* (n=1), *PIK3CA* (n=1), *PTEN* (n=1), and *JAK2* (n=1) (Figure [1](#F1){ref-type="fig"}).

###### The location-specific recurrence of somatic variants in the 43 cancer panel genes

  Gene       Variants^a^             Mutated samples   \% of mutated samples   COSMIC counts   COSMIC ID
  ---------- ----------------------- ----------------- ----------------------- --------------- --------------------------------------------------------------------------
  *APC*      *p.Glu1464ValfsTer8*    2                 1.90%                   45              COSM1432412; COSM19694; COSM41622; COSM41622; COSM41622; COSM5030795
  *ARID1A*   *p.Asp1850ThrfsTer33*   5                 4.70%                   27              COSM1341426; COSM133001; COSM1666860
  *ARID1A*   *p.Gln1334del/dup*      23                21.50%                  23              COSM1341408; COSM298325; COSM1578346; COSM133030; COSM51218; COSM1238047
  *ARID1A*   *p.Gly87del*            2                 1.90%                                   (-)
  *BCOR*     *p.Gln1174ThrfsTer8*    3                 2.80%                   5               COSM1683572; COSM3732385
  *BRAF*     *p.Pro403LeufsTer8*     2                 1.90%                   7               COSM1448632; COSM5347158; COSM5347157
  *CCND1*    *p.Glu280del*           7                 6.50%                   3               COSM931394
  *CDH1*     *p.Leu15del*            5                 4.70%                                   (-)
  *CR1*      *p.Arg2194Ter*          10                9.30%                   20              COSM301989
  *ERBB2*    *p.Arg678Gln*           4                 3.70%                   23              COSM978678; COSM436498
  *ERBB2*    *p.Ser310Phe*           2                 1.90%                   51              COSM48358; COSM1666868
  *ERBB2*    *p.Val842Ile*           2                 1.90%                   26              COSM14065; COSM1666633
  *ERBB3*    *p.Val104Met*           2                 1.90%                   21              COSM20710
  *FBXW7*    *p.Arg385His*           3                 2.80%                   41              COSM117308
  *HLA-B*    *p.Glu69Val*            2                 1.90%                   3               COSM4598273
  *KRAS*     *p.Gly13Asp*            5                 4.70%                   5039            COSM532
  *LARP4B*   *p.Thr163HisfsTer47*    2                 1.90%                   27              COSM1638669; COSM4968611
  *MVK*      *p.Ala141ArgfsTer18*    2                 1.90%                   17              COSM1241457
  *PIK3CA*   *p.His1047Arg*          4                 3.70%                   2115            COSM775
  *PGM5*     *p.Ile98Val*            3                 2.80%                   47              COSM1109610
  *RHOA*     *p. Arg5Gln/Trp*        3                 2.80%                   23              COSM446704; COSM190569; COSM4770224; COSM4770223
  *RHOA*     *p.Thr37Ala/Ile*        2                 1.90%                   3               COSM5064959; COSM1223700
  *RHOA*     *p.Tyr42Cys*            2                 1.90%                   22              COSM2849892; COSM4770225
  *TP53*     *p.Arg248Trp*           2                 1.90%                   56              COSM144150
  *TP53*     *p.Arg342Ter*           2                 1.90%                   151             COSM11073
  *TP53*     *p.Cys275Tyr*           2                 1.90%                   62              COSM10893
  *TP53*     *p.Val173Leu*           2                 1.90%                   65              COSM43559
  *ZBTB20*   *p.Pro619LeufsTer43*    5                 4.70%                   26              COSM267785

^a^Recurrent mutations observed in at least two samples.

![Summary of somatic mutations in 107 gastric cancer samples according to molecular subtype](oncotarget-08-69888-g001){#F1}

Genetic alterations of the RTK/RAS/MAPK or/and PI3K/AKT/mTOR pathways were detected in 34.6% of GC cases (37 individual cases) (Figure [2](#F2){ref-type="fig"}). Receptor tyrosine kinase (RTK) genomic alterations including *ERBB2* (n=13), *EGFR* (n=5), *FGFR2* (n=3) and *KDR* (n=4) were detected in 20.5% of GC cases (n=22). Thirteen samples (12.2% of GC) harbored ERBB2 alterations, 8 contained somatic base substitutions and 5 harbored amplifications, with these events being mutually exclusive. Genetic alterations of *PTEN* (n=4), *PIK3CA* (n=11), *K*RAS (n=11), *BRAF* (n=3) and *MTOR* (n=6) were detected in 25.2% of GC cases (n=27). Ten cases (9.4%) harbored mutated *PIK3CA* and *KRAS* G13D co-existed in 4 cases (Figure [2](#F2){ref-type="fig"}).

![Therapeutic implications of somatic genomic alterations in 107 clinical gastric cancer cases](oncotarget-08-69888-g002){#F2}

Molecular subtype classification and clinical phenotype {#s2_4}
-------------------------------------------------------

We classified molecular subtypes using genomic data according to subtypes derived by TCGA and correlated clinical covariates of 107 GC patients with those molecular subtypes (Table [4](#T4){ref-type="table"}). The EBV subtype (6.5% of GC) was significantly enriched in EBV burden and characterized as uncommon histological subtype (Table [5](#T5){ref-type="table"}). In the EBV subtype, no samples with a *TP53* mutation were detected, but mutations of *ARID1A* (4 cases, 57.1%), *CDH1* (3 cases, 42.9%), *PIK3CA* (2 cases, 28.6%) and *RHOA* (2 cases, 28.6%) were present with a relatively high frequency. Genetic alterations of the *JAK2* and *PDCD1LG2* genes were not detected in the EBV subgroup. Only one case harbored the mutant *CD274* (Figure [1](#F1){ref-type="fig"} & Table [4](#T4){ref-type="table"}).

###### Somatic mutations in each subtype

  Somatic mutations   EBV (N=7)   MSI (N=19)   CIN (N=46)   GS (N=35)   *P* value                         
  ------------------- ----------- ------------ ------------ ----------- ----------- ------- ----- ------- ------------
  TP53                0           0.0%         5            26.3%       26          56.5%   10    28.6%   0.003^*a*^
  ACVR1B              0           0.0%         1            5.3%        1           2.2%    0     0.0%    0.534
  ALK                 0           0.0%         3            15.8%       2           4.3%    1     2.9%    0.232
  APC                 2           28.6%        1            5.3%        8           17.4%   1     2.9%    0.050
  ARID1A              4           57.1%        14           73.7%       12          26.1%   9     25.7%   0.000^*a*^
  BCOR                1           14.3%        9            47.4%       2           4.3%    0     0.0%    0.016^*a*^
  BRAF                0           0.0%         3            15.8%       0           0.0%    0     0.0%    0.003^*a*^
  CBWD1               0           0.0%         0            0.0%        1           2.2%    1     2.9%    1.000
  CCND1               0           0.0%         3            15.8%       2           4.3%    2     5.7%    0.323
  CD274               1           14.3%        0            0.0%        0           0.0%    0     0.0%    0.065
  CDH1                3           42.9%        1            5.3%        3           6.5%    4     11.4%   0.052
  CIC                 0           0.0%         5            26.3%       3           6.5%    2     5.7%    0.082
  CR1                 0           0.0%         5            26.3%       2           4.3%    8     22.9%   0.220
  CTNNB1              1           14.3%        2            10.5%       0           0.0%    2     5.7%    0.054
  EGFR                0           0.0%         4            21.1%       0           0.0%    1     2.9%    0.005^*a*^
  ERBB2               0           0.0%         5            26.3%       2           4.3%    1     2.9%    0.028^*a*^
  ERBB3               0           0.0%         5            26.3%       2           4.3%    2     5.7%    0.049^*a*^
  FBXW7               0           0.0%         3            15.8%       3           6.5%    1     2.9%    0.301
  FGFR2               0           0.0%         2            10.5%       0           0.0%    0     0.0%    0.057
  HLA-B               0           0.0%         3            15.8%       2           4.3%    0     0.0%    0.088
  IRF2                0           0.0%         2            10.5%       1           2.2%    1     2.9%    0.429
  JAK2                0           0.0%         1            5.3%        1           2.2%    0     0.0%    0.534
  KDR                 0           0.0%         3            15.8%       1           2.2%    0     0.0%    0.046^*a*^
  KRAS                0           0.0%         5            26.3%       1           2.2%    0     0.0%    0.002^*a*^
  LARP4B              0           0.0%         3            15.8%       1           2.2%    0     0.0%    0.046^*a*^
  MDM2                0           0.0%         1            5.3%        0           0.0%    0     0.0%    0.243
  MEDAG               0           0.0%         2            10.5%       0           0.0%    0     0.0%    0.057
  MLH1                0           0.0%         2            10.5%       0           0.0%    0     0.0%    0.057
  MSH2                0           0.0%         4            21.1%       1           2.2%    0     0.0%    0.009^*a*^
  MTOR                0           0.0%         3            15.8%       3           6.5%    0     0.0%    0.111
  MVK                 0           0.0%         4            21.1%       0           0.0%    0     0.0%    0.002^*a*^
  MYC                 1           14.3%        0            0.0%        0           0.0%    0     0.0%    0.065
  PGM5                1           14.3%        4            21.1%       0           0.0%    0     0.0%    0.001^*a*^
  PIK3CA              2           28.6%        7            36.8%       1           2.2%    0     0.0%    0.000^*a*^
  PTEN                0           0.0%         2            10.5%       0           0.0%    1     2.9%    0.096
  RHOA                2           28.6%        1            5.3%        2           4.3%    4     11.4%   0.139
  SMAD4               0           0.0%         1            5.3%        1           2.2%    0     0.0%    0.534
  STK11               0           0.0%         1            5.3%        1           2.2%    0     0.0%    0.534
  ZBTB20              0           0.0%         5            26.3%       0           0.0%    0     0.0%    0.000^*a*^
  Mutation rate       2.6                      6.6                      1.8                 1.5           

^*a*^*p* value less than 0.05.

Abbreviations: CIN, chromosomal instability, EBV, Epstein-Barr virus; GS, genomically stable; MSI, microsatellite instability. Fisher\`s exact test was performed to evaluate differences in the respective proportions of somatic mutations between subgroups.

###### Patient characteristics according to molecular subtype

                              EBV (n=7)   MSI (n=19)   CIN (n=46)   GS (n=35)   *P* value                        
  --------------------------- ----------- ------------ ------------ ----------- ----------- ------- ---- ------- -------
  **Age**                                                                                                        
  ≤50                         0           0.0%         1            5.3%        3           6.5%    6    17.1%   0.580
  51 ∼60                      2           28.6%        1            5.3%        9           19.6%   6    17.1%   
  61 ∼70                      1           14.3%        3            15.8%       13          28.3%   8    22.9%   
  71 ∼ 80                     3           42.9%        12           63.2%       16          34.8%   13   37.1%   
  \>80                        1           14.3%        2            10.5%       5           10.9%   2    5.7%    
  **Sex**                                                                                                        
  Female                      1           14.3%        8            42.1%       16          34.8%   11   31.4%   0.660
  Male                        6           85.7%        11           57.9%       30          65.2%   24   68.6%   
  **Lauren Class**                                                                                               
  Diffuse                     3           42.9%        2            10.5%       9           19.6%   14   40.0%   0.069
  Intestinal                  2           28.6%        15           78.9%       26          56.5%   15   42.9%   
  Mixed                       2           28.6%        2            10.5%       11          23.9%   6    17.1%   
  **WHO Class**                                                                                                  
  Tubular                     2           28.6%        17           89.5%       32          69.6%   18   51.4%   0.000
  Mucinous                    0           0.0%         0            0.0%        2           4.3%    1    2.9%    
  Poorly cohesive             0           0.0%         0            0.0%        5           10.9%   9    25.7%   
  Mixed                       1           14.3%        1            5.3%        7           15.2%   7    20.0%   
  Uncommon                    4           57.1%        1            5.3%        0           0.0%    0    0.0%    
  **pT stages**                                                                                                  
  T1a/ T1b                    2           28.6%        2            10.5%       10          21.7%   10   28.6%   0.778
  T2                          1           14.3%        3            15.8%       4           8.7%    3    8.6%    
  T3                          1           14.3%        9            47.4%       17          37.0%   11   31.4%   
  T4a/ T4b                    3           42.9%        5            26.3%       15          32.6%   11   31.4%   
  **p N stages**                                                                                                 
  N0                          3           42.9%        10           52.6%       16          34.8%   11   31.4%   0.802
  N1                          1           14.3%        3            15.8%       7           15.2%   5    14.3%   
  N2                          1           14.3%        4            21.1%       9           19.6%   6    17.1%   
  N3                          2           28.6%        2            10.5%       14          30.4%   13   37.1%   
  **M stages**                                                                                                   
  M0                          6           85.7%        19           100.0%      43          93.5%   34   97.1%   0.351
  M1                          1           14.3%        0            0.0%        3           6.5%    1    2.9%    
  **AJCC Stages**                                                                                                
  Stages IA/IB                3           42.9%        4            21.1%       11          23.9%   11   31.4%   0.605
  Stages IIA/IIB              1           14.3%        9            47.4%       13          28.3%   3    8.6%    
  Stages IIIA/IIIB/IIIC       2           28.6%        6            31.6%       19          41.3%   20   57.1%   
  Stage IV                    1           14.3%        0            0.0%        3           6.5%    1    2.9%    
  **Anatomical regions**                                                                                         
  Antrum                      1           14.3%        15           78.9%       25          54.3%   13   37.1%   0.004
  Antrum_Body                 1           14.3%        0            0.0%        2           4.3%    2    5.7%    
  Fundus_Body                 4           57.1%        4            21.1%       10          21.7%   18   51.4%   
  GEJ_Cardia                  1           14.3%        0            0.0%        7           15.2%   0    0.0%    
  Diffuse                     0           0.0%         0            0.0%        0           0.0%    1    2.9%    
  Pylorus                     0           0.0%         0            0.0%        2           4.3%    1    2.9%    
  **Lymphatic invasion**                                                                                         
  Positive                    4           57.1%        17           89.5%       34          73.9%   21   60.0%   0.125
  Negative                    3           42.9%        2            10.5%       12          26.1%   13   37.1%   
  Missing                     0           0.0%         0            0.0%        0           0.0%    1    2.9%    
  **Venous invasion**                                                                                            
  Positive                    2           28.6%        1            5.3%        7           15.2%   5    14.3%   0.416
  Negative                    5           71.4%        18           94.7%       39          84.8%   29   82.9%   
  Missing                     0           0.0%         0            0.0%        0           0.0%    1    2.9%    
  **Perineural invasion**                                                                                        
  Positive                    4           57.1%        6            31.6%       25          54.3%   17   48.6%   0.391
  Negative                    3           42.9%        13           68.4%       21          45.7%   17   48.6%   
  Missing                     0           0.0%         0            0.0%        0           0.0%    1    2.9%    
  ***H. pylori* infection**                                                                                      
  Negative                    3           42.9%        8            42.1%       21          45.7%   9    25.7%   0.290
  Positive                    4           57.1%        11           57.9%       25          54.3%   26   74.3%   

Abbreviations: CIN, chromosomal instability, EBV, Epstein-Barr virus; GS, genomically stable; gastric cancer, GC; GEJ, gastroesophageal junction; *H. pylori, Helicobacter pylori;* MSI, microsatellite instability; Mixed, mixed type with tubular and poorly cohesive; pT stage, pathological assessment of the primary tumor; pN stage, pathological assessment of the regional lymph nodes; Uncommon, uncommon histologic variants.

The MSI subtype (17.8% of GC) showed instability in one more locus in the MSI assay. The MSI subtype presented with an elevated mutation rate (6.6 per case) and was characterized by alterations of genes involved in mismatch repair. Almost all cases with mutations in *MLH1* (n=2/2) and *MSH2* (n=4/5) were included in the MSI subtype. Mutations of *ARID1A* (73.7%), *BCOR* (47.4%), *BRAF* (15.8%), *EGFR* (21.1%), *ERBB2* (26.3%), *ERBB3* (26.3%), *KDR* (15.8%), *KRAS* (26.3%), *LARP4B* (15.8%), *MSH2* (21.1%), *MVK (21.1%), PGM5* (21.1%), *PIK3CA* (36.8%) and *ZBTB20* (26.3%) were observed with statistical significance. Interestingly, we observed that mutations of *ZBTB20* were limited to the MSI group (Table [4](#T4){ref-type="table"})*.*

The CIN subtype (43.0% of GC) was also characterized by a relatively low-somatic mutation rate (1.8 per case) and a high frequency of *TP53* mutations. In the CIN subtype, we observed amplifications of *CCND1, CCNE1, ERBB2, FGFR2*, *KRAS, MYC, PIK3CA* and *JAK2,* and a deletion of *PTEN* among the 43 genes included in the Next-Generation Sequencing (NGS) panel. Ten cases (21.7% in the CIN subtype) harbored CNVs of genes belonging to the RTK/RAS/MAPK and PI3K/PTEN/AKT pathways (Figure [2](#F2){ref-type="fig"}). CNV detection using a targeted NGS panel of 43 genes represented 30.4 % of the CIN subtype (n=14/46) (Figure [1](#F1){ref-type="fig"}).

The GS subtype (32.7 % of GC) was characterized by a lack of EBV infection, MSI and somatic CNAs. The GS subtype showed the lowest mutation rate (1.5 per case) (Table [4](#T4){ref-type="table"}).

Prognosis analysis in 107 gastric cancer patients {#s2_5}
-------------------------------------------------

Among the 107 GC patients, the date of last follow-up (months), loco-regional recurrence, distant metastasis, and cause of death were obtained from 72 patients. The median follow up period was 459.5 days, and there were 19 (26.4%) and 12 (16.7%) cases of gastric cancer relapse and gastric cancer-related death, respectively. We conducted a survival analysis but did not observe a substantial difference in overall survival (*p*= 0.898) or relapse-free survival (RFS, *p*=0.548) among the four GC subtypes (Figure [3](#F3){ref-type="fig"} (a) & (b)). The classification based on AJCC stages showed significant differences in overall survival (*p*= 0.001) or RFS (*p* \<0.001) (Figures [3](#F3){ref-type="fig"} (c) & (d)). Multivariate analysis showed mutant *MTOR* gene (hazard ratio \[HR\]:9.26, *p*= 0.002, 95% CI: 2.22 -- 38.58), AJCC stages III (HR: 1.9, *p*= 0.013, 95% CI: 1.14 - 3.16), AJCC stages IV (HR: 2.15, *p*= 0.000, 95% CI: 1.40 - 3.30) and mutant *CCND1* gene (HR: 5.71, *p*= 0.028, 95% CI: 1.21 -- 27.0) were associated with the relapse of GC.

![Kaplan-Meier **(a)** relapse-free survival (RFS) and **(b)** gastric cancer-specific survival (GCSS) curves were stratified by molecular subtypes of gastric cancer (EBV, MSI, CIN, and GS). Kaplan-Meier **(c)** RFS and **(d)** GCSS curves were analyzed by AJCC stage.](oncotarget-08-69888-g003){#F3}

DISCUSSION {#s3}
==========

We analyzed germline mutations with paired non-tumor and GC tissue samples in 107 Korean patients. Two cases harbored a likely pathogenic variant (NM_004360.4: c. 2494 G\>A, *p.V832M*) in the *CDH1* gene. A V832M mutation has been identified in a hereditary diffuse gastric cancer (HDGC) in a Japanese family. The probands were diagnosed at the age of 56 \[[@R21]\]. This mutation were functionally characterized as a pathogenic mutation \[[@R22]\] and it was also detected in familial lobular breast cancer patients with the wild type *BRCA1/2* gene \[[@R23]\]. Two cases with V832M were diagnosed at age 66 and 75, in this study, respectively. Both cases were advanced GC in stage IIB at diagnosis and the family history of GC was not known.

According to the results of somatic variants, the Q1334del/dup (n=23/52) in *ARID1A* and L15del (n=6/13) in *CDH1* were detected at a frequency of 5∼33% of altered alleles in tumor tissue (Table [3](#T3){ref-type="table"} & [Supplementary 2](#SD2){ref-type="supplementary-material"}). The in-frame indel (Q1334del/dup), which increases the amount of the ARID1A protein in the nucleus and restores its tumor suppressor functions, has also been reported in GC samples \[[@R24]\]. This single nucleotide polymorphism (SNP) were also occasionally reported in COSMIC database (COSMIC v78) and pancreatic cancers \[[@R25]\]. A three-nucleotide deletion c.44_46del TGC (L15del) in exon 1 of *CDH1,* which is in the signal peptide region of the E-cadherin protein, was also identified in Chinese GC patients, whereas it was not detected in 240 controls \[[@R26]\] and endometrial carcinomas \[[@R27]\]. RHOA belongs to the Rho family, which functions in the regulation of the actin cytoskeleton, and functional evidence indicates that mutant *RHOA* works in a gain-of-function manner in this gene \[[@R28]\]. An *RHOA* mutation was observed in 8.4% of GC cases (n=9/107), with mutations in the Arg5, Gly17, Thr37, Tyr42 and Glu64 residues (Table [3](#T3){ref-type="table"} & [Supplementary 2](#SD2){ref-type="supplementary-material"}). Among these mutations, the Arg5, Gly17, and Tyr42 residues are recurrently detected in GC \[[@R28], [@R29]\].

EBV-infected GC constitutes 5-10% of all GC cases \[[@R9], [@R10]\] and the Cancer Genome Atlas project demonstrated that EBV-infected GC is one of four molecular subtypes \[[@R28]\]. We also demonstrated that EBV-infected GC grouped as a molecular subtype. As in the EBV-subtype, *ARID1A* mutations (4 cases, 57.1%) were prevalent, and no samples with a *TP53* were detected. The frequency of *ARID1A* and *TP53* mutations were similar to the TCGA data \[[@R28]\]. Inhibitors of the PI3K/AKT/mTOR pathway, JAK2 pathway and *PD-1/PD-L1, PD-L2* pathway are considered as potentially applicable targeted therapies in EBV-infected GC \[[@R4], [@R30]\]. However, only 28.6 % of EBV-infected GC harbored *PIK3CA* mutations (n=2/7), and drug related amplifications of *JAK2, CD274*, *PDCD1LG2* and ERBB2 were not detected in the EBV subtype (Figure [2](#F2){ref-type="fig"}). To provide applicable therapeutic options, the genetic alterations of *PIK3CA AK2, CD274*, *PDCD1LG2* and *ERBB2* should be further validated with large-scale EBV-infected GC.

We observed that the MSI subtype was associated with hyper-mutations in genes and was characterized by a more favorable prognosis than other molecular subtypes. Both the TCGA and ACRG classifications also characterized the MSI subtype by the high mutation frequency and best prognosis \[[@R6], [@R28]\]. For intestinal type GC, patients with a good prognosis were characterized by a high mutation rate and microsatellite instability. Further, mutations of *PIK3CA* (29.4%) and *KRAS* (26.5%) were represented in good prognosis subgroup \[[@R31]\]. In our study, mutations of *KRAS* (26.3%) and *PIK3CA* (36.8%) were present with statistical significance in the MSI subtype, and *KRAS* G13D (4 cases) and *PIK3CA* H1047R mutations (3 cases) were frequently observed (Table [2](#T2){ref-type="table"}). In addition, *PIK3CA* H1047R mutations were also frequently detected in the MSI subtype in a previous study \[[@R6]\]. The genetic alteration of *ZBTB20* (P619fs*\**43, n=5) was limited to the MSI group. This SNP (P619fs*\**43; rs758277701; COSM267785) also was limited to the MSI group and similar trend was observed (20% of MSI) in TCGA data \[[@R28]\]. The clinical significance of this variation should be evaluated through further studies.

The distribution of four GC subgroups based on the TCGA \[[@R28]\] and our data were similar (EBV, 8.8% vs. 6.5%; MSI, 21.7% vs. 17.8%; GS, 19.7% vs. 32.7 %; CIN, 49.8 % vs. 43.0 %). Furthermore, the proportion of EBV (6.4% vs. 6.5%), MSI (9.2% vs. 17.8%) and CIN subtype (51 % vs. 43.0 %) in Korean GC were also similar to our data. \[[@R32], [@R33]\].

Genetic alterations of the RTK/RAS/MAPK and PI3K/AKT/mTOR pathways were detected in 34.6% of GC cases (n=37) (Figure [2](#F2){ref-type="fig"}). Thirteen samples (12.2% of GC) harbored *ERBB2* alterations, 8 contained somatic base substitutions and 5 harbored amplifications, with these events being mutually exclusive. S310F (two cases) and V842I substitutions (two cases) in *ERBB2* were recurrently detected in this study and have been functionally characterized as activating and sensitive to lapatinib in ERBB2-negative breast cancers. The functions of *ERBB2* R678Q, which was also recurrently detected in this study, related to anti-ERBB2 (HER2)-targeted therapy has not been tested \[[@R34]\]. Ten cases (9.4%) harbored mutated *PIK3CA*, and *KRAS* G13D co-existed in 4 cases (Figure [2](#F2){ref-type="fig"}). Effects of the co-existence of genetic alterations of *PIK3CA* and *KRAS* on response to therapy are yet to be evaluated \[[@R4]\]. Dual PI3K and STAT3 blockade using NVP-BKM120 and AG490 (STAT3 inhibitor) showed a synergistic effect in GC cells harboring mutated *KRAS* by inducing apoptosis \[[@R35]\].

These biomarkers may facilitate enrollment of GC patients into clinical trials evaluating targeted therapies and provide the basis for developing solid therapeutic approaches in Korean GC patients \[[@R36]--[@R38]\].

Molecular classification based on four GC subtypes showed no significant survival differences in overall survival (*p*= 0.898) or RFS (*p*=0.548) in this dataset. And, ACRG classification-based subtypes also showed no significant association with survival in Korean GC \[[@R33]\]. Therefore, we thought that predicting prognosis for Korea GC patients might be performed more simply and effectively using AJCC stage \[[@R39]\] rather than molecular classification.

We classified molecular subtypes of gastric cancer according to the TCGA system using a targeted NGS panel of 43 genes, EBV, MSI, *H. pylori* and SNP array. The 43 gene cancer panel consisted of significantly mutated genes from the TCGA and ACRG cohort \[[@R6], [@R28], [@R40]\], genes associated with new targeted therapy of GC (*EGFR, ERBB2, FGFR2,* and *KDR*) and hereditary cancer syndromes (*CDH1, MSH2, MLH1, STK11,* and *TP53*) \[[@R12]\]. We demonstrated 1) the distribution of GC subtypes according to TCGA molecular group, 2) heritable genetic alterations, 3) environmental factors (*EBV* and *H. pylori*), 4) somatic genetic aberrant profiles including driver mutations and drug-targeted genetic alterations, and 5) histopathological features in Korean GC patients.

MATERIALS AND METHODS {#s4}
=====================

Subject selection {#s4_1}
-----------------

We obtained a total of 107 gastric tumors and matched non-tumor tissue samples from Yonsei University Wonju Medical Center Biobank (n=138, 69 paired samples) and Samkwang Medical Laboratory Biobank (n= 76, 38 paired samples). Tumor samples were obtained from patients who had not received prior chemotherapy or radiotherapy. The gastric cancer tissues consisted of 69 fresh-frozen (FF) paired tumor and non-tumor tissue samples and 38 formalin-fixed paraffin-embedded (FFPE) paired tumor and non-tumor tissue samples. Clinical data, including age, sex, clinical follow-up data, and pathologic reports, were provided from the tissue source institutions. The histologic classification of gastric carcinoma has previously been based on Lauren's criteria \[[@R2]\] and the 2010 WHO classification system \[[@R3]\]. Tumor TNM stage assignment was evaluated for consistency with the 7th Edition of the TNM classification by the American Joint Committee on Cancer (AJCC) \[[@R39]\]. Pathologic findings were reviewed by experienced gastrointestinal pathologists (S.N.K. and M.C.). The study was approved by the Institutional Review Boards of Samkwang Medical Laboratories and Yonsei University Wonju College of Medicine.

DNA preparation {#s4_2}
---------------

DNA was extracted from FFPE tumor and adjacent non-tumor gastric tissues using a QIAamp DNA extraction kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. H&E-stained sections from FFPE blocks were reviewed by a board-certified pathologist, and representative sections with tumor content or benign tissue were identified. A G-DEX genomic DNA extraction kit (Intron Biotechnology, Korea) was used for FF tumor and matched non-tumor FF tissues according to the manufacturer's protocol. The quality and concentration of genomic DNA (gDNA) was evaluated by Nanodrop (ND-1000; Thermo Scientific, DE, USA) and the Agilent 2200 Tape Station system (Agilent Technologies, CA, USA) with Genomic DNA Screen Tape according to the manufacturer's instructions. The DNA Integrity Number (DIN) for determining the integrity of gDNA was calculated from the electrophoretic trace on the 2200 Tape Station system according to the manufacturer's instructions. The average value (range) of total DNA concentration in FFPE tissue and FF tissue was 322.7 (12.6 ∼ 322.9) ng/uL and 952.8 (76.0 ∼ 3756.0) ng/uL, respectively. The average value (range) of DIN in FFPE tissue and FF tissue was 2.9 (1.5 ∼ 6.4) and 5.6 (1.4 ∼ 8.4), respectively.

Detection of EBV and *H. pylori* infection {#s4_3}
------------------------------------------

EBV infection was detected using the Real-Q EBV quantification kit (Biosewoom, Seoul, Korea) and CFX96 real-time PCR system (Bio-Rad, USA) following the manufacturer's recommendations.

*H. pylori* infection was detected using Giemsa stain (n=93) or PCR amplification and sequencing (n=14). Primers for PCR and sequencing were derived from a known sequence of the 23S rRNA gene (GenBank Accession No. U27270), as previously described (sense, 5\'-CGT AAC TAT AACGGT CCT AAG-3\', positions 2365 to 2385; antisense, 5\'-TTA GCT AAC AGA AAC ATC AAG-3\', positions 2635 to 2653) \[[@R41]\].

Configuration of a gastric cancer-related target gene panel for Korean gastric cancer patients {#s4_4}
----------------------------------------------------------------------------------------------

The cancer panel consisted of genes based on the Mutation Analysis (MutSig 2CV v3.1) results of the Cancer Genome Atlas (TCGA) project (<http://gdac.broadinstitute.org/runs/analyses_latest/reports/cancer/STAD-TP/index.html>, accessed at 2015.03.30) \[[@R28], [@R40]\] and significantly mutated genes in the Asian Cancer Research Group (ACRG) cohort and SMC-2 cohort in primary gastric cancer tissues \[[@R6]\]. Genes associated with new targeted therapy of GC (*EGFR, ERBB2, FGFR2,* and *VEGFR2* (*KDR*)) and hereditary cancer syndromes (*CDH1, MSH2, MLH1, STK11,* and *TP53*) were also included in the cancer panel \[[@R12]\].

The entire length of the ROI of the NGS panel of 43 genes was 124,132 bp. To validate the performance of the NGS panel of 43 genes, NA12878 reference materials were used 7 times in 3 batches. The panel average coverage is 1,710× with 97% of targeted bases covered \>20×. We downloaded the VCF file for NA12878 (<https://www.ncbi.nlm.nih.gov/variation/tools/get-rm/>) and then compared it to 7 variant call sets of our control reference materials (NA12878). The sensitivity and specificity of the 43 gene cancer panel were 96.4 % (95% CI: 0.941 -- 0.979) and 100%, respectively.

Targeted sequencing and data analysis {#s4_5}
-------------------------------------

DNA fragments of matched tumor and non-tumor tissues were enriched by solution-based hybridization capture, followed by sequencing with the Illumina Hiseq2500 platform (Illumina, San Diego, CA, USA) with the 2 × 125 bp paired-end read module. gDNA was sheared using an Adaptive Focused Acoustics (AFA)™ with the Covaris Focused-ultrasonicator (Covaris, Inc., Woburn, MA, USA). The quality and quantity of sheared DNA were assessed using the Agilent 2200 Tape Station system with Agilent D1000 ScreenTape (Agilent Technologies, USA) according to the manufacturer's instructions. Capture probes for the coding exons of 43 genes ([Supplementary 1](#SD1){ref-type="supplementary-material"})were generated by Celemics (Seoul, Korea). Purification and clean-up of samples were performed using a DynaMag™-50 Magnet (Thermo Fisher Scientific Inc., Waltham, MA, USA) with Agencourt^®^ AMPure^®^ XP Kit (Beckman Coulter, Brea, CA, USA). NGS library amplification was performed using a KAPA Library Amplification Kit (Kapa Biosystems, Inc., Wilmington, MA, USA) according to the manufacturer's instructions. Library preparation, hybridization, capture procedure, and sequencing on the Illumina HiSeq2500 genome analyzer were performed by Celemics according to the protocols recommended by the Celemics User Manual Ver 2.1 (<http://www.celemics.com/home/>).

The generated reads were trimmed and filtered by Trimmomatic \[[@R42]\] and then mapped against the UCSC hg19 Genome Reference Consortium Human Reference 37 (GRCh37) (<http://genome.ucsc.edu/>) using the Burrows-Wheeler Aligner (BWA) \[[@R43]\]. Picard (<http://broadinstitute.github.io/picard/>), SAMTools \[[@R44]\], and Genome Analysis Toolkit (GATK, <https://www.broadinstitute.org/gatk/>) \[[@R45]\] were used for post-processing alignments, base quality score recalibration, and short insertion/deletion (indel) realignment. After variant calling, variants were added to the annotation using ANNOVAR (<http://www.openbioinformatics.org/annovar/>)\[[@R46]\] and Variant Effect Predictor (VEP, <http://asia.ensembl.org/info/docs/tools/vep/index.html>). We used Varscan 2 (<http://varscan.sourceforge.net>) \[[@R47]\] for the detection of somatic SNVs and indels.

All acquired candidate variations went through post filters recommended by the authors of these tools. We extracted somatic mutations with Varscan2 and post-filtered with downstream analysis for altered allele frequency in tumors \> 5%, \> 50 x coverage, exonic variants, and population frequency 0.005 less than in the 1000 Genome Project (<http://www.1000genomes.org>), ESP6500 (<http://evs.gs.washington.edu/EVS/>), and Exome Aggregation Consortium (ExAC, <http://exac.broadinstitute.org/>). We excluded somatic variants detected \>2 times in non-tumor tissue. We identified germline variations post-filtered with downstream analysis for altered allele frequency \> 30%, \> 50x coverage, and population frequency less than 0.01 in the 1000 Genome Project, ESP6500, and ExAC databases. These variants were present in both GC and matched non-tumor\" tissue. Visual inspection of filtered calls was performed using Integrated Genomics Viewer 2.3 software (IGV; Broad Institute, Cambridge, MA, USA).

CNV analysis {#s4_6}
------------

CNV analysis of the NGS panel of 43 genes was performed with dispersion and the Hidden Markov Model (HMM) method with normalized counts in NextGENe v2.4.1.2 - CNV tool (Softgenetics, State College, PA, USA). The dispersion value was automatically calculated and an HMM was used to merge multiple-exon calls and apply a priori probability. Using the coverage ratio value and the amount of noise in each region, the copy number state of each region in the sample was reported (duplication/normal/deletion) \[[@R48]\]. The NextGENe Viewer (SoftGenetics) was used to visualize the several large CNV calls. To validate the performance of this tool, we compared its results to Her2 immunohistochemistry (IHC) results. Fifty-four cases performed with Her2 IHC consisted of 4 positive cases (score: 3+) and 39 negative cases. We compared the Her2 IHC results and the CNV results from NextGENe-CNV analysis. The sensitivity and specificity of CNV analysis were 75.0% (95% CI: 0.194 -- 0.993) and 100% (95% CI: 0.929 -- 1.0), respectively.

The Infinium^®^ Global Screening Array (Illumina, San Diego, CA, USA) was performed for 69 FF tumor tissues and 22 FFPE tumor tissues according to the manufacturer's recommendations. The hybridized arrays were scanned using the HiScan system (Illumina, San Diego, CA, USA). CNA analysis from single nucleotide polymorphism (SNP) based arrays were performed using GISTIC 2.0. \[[@R49]\]. To eliminate bias from copy number variable regions in healthy individuals, we analyzed CNV in a certain range, including somatic CAN-reported regions in GCs (<http://www.cbioportal.org/>) and dosage-sensitive regions of the genome \[[@R50]\].

Microsatellite instability (MSI) assay {#s4_7}
--------------------------------------

Microsatellite status was assessed by the mononucleotide repeat markers BAT-25, BAT-26, NR-21, NR-24, and NR-27 in tumor and corresponding non-tumor tissues \[[@R51]\]. The five markers were co-amplified in multiplex PCRs performed with Solg2X multiplex PCR Smart mix following the manufacturer's recommendations. The amplified PCR products were analyzed using the ABI 3500Dx system (Applied Biosystems, Foster City, CA, USA) and GeneMarker software (SoftGenetics, PA, USA). Tumors with two or more of the five markers showing instability were judged as high-frequency MSI (MSI-H), and tumors showing instability in only one locus were classified as low-frequency MSI (MSI-L) \[[@R52]\].

Molecular subtype classification and statistical analysis {#s4_8}
---------------------------------------------------------

As with the TCGA classification sequence \[[@R5]\], we also divided GC into EBV, MSI and CIN serially according to the results of EBV, MSI and SNP arrays. The remainder was then classified into the GS subgroup.

Fisher\`s exact and Chi-squared tests were performed to evaluate differences in the respective proportion of several factors between subgroups. Patient follow-up periods were calculated as time between date of surgery and date of last follow-up (months). Relapse-free survival (RFS) was assessed based on the absence of loco-regional recurrence, distant metastasis, and death from any cause. GC-specific survival (GCSS) was calculated only for patients who died from any GC-related cause. Kaplan-Meier survival curves with log-rank tests were performed to compare RFS and GCSS according to AJCC stage and molecular subtype. Cox proportional hazard models were performed to assess the influence of prognostic factors on RFS. All statistical analyses were performed using SPSS 22.0 (SPSS, Chicago, IL, USA). Except for the univariate analysis, a *p* value less than 0.05 was regarded as significant.

SUPPLEMENTARY MATERIALS TABLES {#s5}
==============================
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:   pathological assessment of the primary tumor
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:   uncommon histologic variants

VAF

:   Variant allele frequency

VUS
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